-- Astellas Pharma's (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.
The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.
Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.
During the year, Astellas Pharma booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.
The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.
For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.
Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.